Strategies for improving the 3D printability of decellularized extracellular matrix bioink

Huihui Zhang, Yilin Wang, Zijun Zheng, Xuerong Wei, Lianglong Chen, Yaobin Wu, Wenhua Huang, Lei YangTheranostics 2023 · DOI

TL;DR

Decellularized extracellular matrix (dECM) holds immense promise for creating biomimetic 3D bioprinted tissues due to its native-like properties. However, its inherent poor mechanical stability and low viscosity make it challenging to 3D print. This review explores strategies to overcome these printability issues, paving the way for advanced tissue engineering applications.

What Problem Does This Paper Address?

The ultimate goal of tissue engineering is to create functional, implantable tissues and organs to address the shortage of donors and the risks of immune rejection. 3D bioprinting offers a powerful approach to construct complex, patient-specific tissues by precisely depositing cells and biomaterials. Decellularized extracellular matrix (dECM), derived from native tissues, is an ideal bioink candidate because it retains the intricate physical, chemical, and biological cues of the native microenvironment, which are crucial for cell behavior and tissue development. However, dECM bioinks are notoriously difficult to 3D print. They often suffer from low viscosity and poor mechanical integrity, leading to collapsed structures and a lack of shape fidelity. This "non-printability" severely limits their application in creating robust, functional 3D constructs. This paper addresses this critical challenge by reviewing current methods to improve the 3D printability of dECM bioinks, enabling their broader use in tissue regeneration.

Methods

The paper provides a comprehensive overview of methods for producing and improving dECM bioinks. Key methodological aspects include:

  • Decellularization Techniques: The review categorizes decellularization methods into physical (e.g., freeze-thaw, high hydrostatic pressure, supercritical CO2), chemical (detergents, acids, alkalis), and enzymatic approaches. The choice of method is crucial for preserving ECM components while effectively removing cellular and immunogenic materials.
  • dECM Solubilization: Typically, decellularized tissues are lyophilized, milled into powder, and then solubilized, often using pepsin digestion in acidic conditions, followed by pH neutralization to induce self-assembly into a gel.
  • Printability Enhancement Strategies: This is the core focus. Strategies are broadly divided into:
  • Physical Strategies: These involve providing external support during printing. Examples include using support baths (e.g., thermosensitive hydrogels like gelatin or poloxamers), sacrificial materials (e.g., Pluronic F-127), or incorporating supportive polymeric frameworks like polycaprolactone (PCL) or poly(ethylene/vinyl acetate) (PEVA).
  • Chemical Strategies: These focus on modifying the bioink itself to improve its rheological properties and mechanical stability. This includes:
  • Cross-linking: Incorporating natural or synthetic polymers (e.g., alginate, gelatin methacrylate (GelMA), hyaluronic acid methacrylate (HAMA), polyethylene glycol diacrylate (PEGDA)) that can be cross-linked (e.g., via UV light, ionic interactions, or thermal stimuli) to form more stable hydrogels.
  • Functionalization: Chemically modifying dECM itself, for instance, through methacrylation, to introduce reactive groups that enable photo-crosslinking.
  • Hybrid Bioinks: Combining dECM with other materials to leverage their complementary properties.

Datasets

Not discussed in the paper. The paper is a review article and does not present original experimental data or datasets.

Key Insights and Ideas

  • The "Non-Printable" Dilemma: dECM's rich biological cues are its strength, but its inherent low viscosity and poor mechanical properties are its Achilles' heel for 3D bioprinting. This fundamental trade-off is a central theme.
  • Synergy is Key: No single strategy is a silver bullet. The most successful approaches often combine physical support with chemical modifications to achieve both printability and cell viability.
  • Tailoring to Tissue Type: The optimal decellularization and bioink formulation depend heavily on the source tissue's specific composition and mechanical requirements. What works for bone ECM might not work for skin ECM.
  • The "Biofabrication Window": The concept of a "biofabrication window" highlights the delicate balance required between printability (often linked to higher viscosity/stiffness) and cell function/viability (which can be compromised by harsh conditions).
  • Beyond Simple Extrusion: While extrusion printing is common, advanced techniques like digital light processing (DLP) and coaxial printing are enabling more complex structures and multi-material bioinks.

Key Results

The paper doesn't present quantitative results in the traditional sense, as it's a review. However, it highlights successful applications and improvements demonstrated in cited studies:

  • Improved Shape Fidelity: Strategies like PCL frameworks and sacrificial materials have enabled the printing of complex, shape-stable constructs, including airway-on-a-chip models, breast reconstruction scaffolds, and even functional heart tissue models.
  • Enhanced Mechanical Properties: Chemical modifications (e.g., methacrylation, incorporation of polymers like PEGDA) have significantly increased the compressive modulus and Young's modulus of dECM bioinks, bringing them closer to native tissue mechanical properties. For example, some dERS-crosslinked products achieved moduli up to 86.4 kPa, significantly higher than typical dECM hydrogels.
  • Successful Tissue Mimicry: Bioprinted constructs using improved dECM bioinks have demonstrated successful recapitulation of native tissue microenvironments, leading to enhanced cell proliferation, differentiation, and functional recovery in various models (e.g., kidney microtissues, liver microtissues, skin equivalents, intestinal villus models).
  • Clinical Translation Potential: The review points to approved dECM products for tissue repair, underscoring the growing clinical relevance of this field.

Limitations and Future Work

  • Standardization Challenges: A major limitation is the batch-to-batch variability in dECM derived from different tissues and processing methods. Standardized decellularization and evaluation criteria are urgently needed.
  • Immune Response Control: While decellularization aims to remove immunogenic components, residual cellular debris and DNA can still trigger inflammatory responses. Balancing bioactivity with immunogenicity remains a challenge.
  • Vascularization: Creating vascularized tissues, especially for larger organ constructs, is a significant hurdle. Effective vascularization procedures for bioprinted dECM tissues are still under development.
  • Complexity of Whole Organs: While progress has been made in mimicking tissue microenvironments, the functional complexity of whole organs presents a formidable challenge for current dECM bioprinting.
  • Regulatory Hurdles: Bioprinted scaffolds are complex products that straddle the lines between biologics, pharmaceuticals, and medical devices, posing regulatory challenges.

Future work should focus on developing more standardized and reproducible dECM production methods, creating bioinks with precisely controlled mechanical properties and degradation rates, and advancing 3D bioprinting technologies for creating complex, vascularized tissues and organs. The integration of cell biology, material science, physics, and mechanical engineering will be crucial for realizing the full clinical potential of dECM-based bioprinting.

Summary updated

Abstract

3D bioprinting is a revolutionary technology capable of replicating native tissue and organ microenvironments by precisely placing cells into 3D structures using bioinks. However, acquiring the ideal bioink to manufacture biomimetic constructs is challenging. A natural extracellular matrix (ECM) is an organ-specific material that provides physical, chemical, biological, and mechanical cues that are hard to mimic using a small number of components. Organ-derived decellularized ECM (dECM) bioink is revolutionary and has optimal biomimetic properties. However, dECM is always "non-printable" owing to its poor mechanical properties. Recent studies have focused on strategies to improve the 3D printability of dECM bioink. In this review, we highlight the decellularization methods and procedures used to produce these bioinks, effective methods to improve their printability, and recent advances in tissue regeneration using dECM-based bioinks. Finally, we discuss the challenges associated with manufacturing dECM bioinks and their potential large-scale applications.
BibTeX
@inproceedings{zhang2023strategies,
  author = {Huihui Zhang and Yilin Wang and Zijun Zheng and Xuerong Wei and Lianglong Chen and Yaobin Wu and Wenhua Huang and Lei Yang},
  title = {{Strategies for improving the 3D printability of decellularized extracellular matrix bioink}},
  booktitle = {Theranostics},
  year = {2023},
  doi = {10.7150/thno.81785},
}
Figure